This trial is developing a care model to help people with metastatic lung cancer cope with uncertainty and understand their prognosis and treatment goals, so they can live well with cancer.
- Non-Small Cell Lung Cancer
- Palliative Care
- Non-Small Cell Lung Cancer (EGFR Positive)
- Stage IV Non-small Cell Lung Cancer
- Targeted Therapy
- ALK-positive Non-small Cell Lung Cancer
1 Primary · 4 Secondary · Reporting Duration: 24 weeks
Rate of acceptability at 12 weeks
Rate of acceptability at 24 weeks
Distress related to prognostic uncertainty
Documentation of Goals and Values
1 Treatment Group
1 of 1
15 Total Participants · 1 Treatment Group
Primary Treatment: POISE · No Placebo Group · N/A
BehavioralExperimental Group · 1 Intervention: POISE · Intervention Types: Behavioral
Screening: ~3 weeks
Reporting: 24 weeks
Who is running the clinical trial?
American Lung AssociationOTHER
28 Previous Clinical Trials
9,714 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
2,730 Previous Clinical Trials
31,219,408 Total Patients Enrolled
Laura A Petrillo, MDPrincipal InvestigatorMassachusetts General Hospital
1 Previous Clinical Trials
210 Total Patients Enrolled
Age 18+ · All Participants · 5 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
You are currently taking medication specifically designed to treat your condition.
You are a patient at the MGH Cancer Center.
Frequently Asked Questions
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there open slots available for the current clinical trial?
"Clinicaltrials.gov indicates that this particular medical trial, which was first announced on October 1st 2022, is not presently seeking participants. Nonetheless, there are 2140 other studies currently recruiting patients." - Anonymous Online Contributor